122 related articles for article (PubMed ID: 8874331)
1. Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: a National Cancer Institute of Canada Clinical Trials Group study.
Perrault D; Eisenhauer EA; Pritchard KI; Panasci L; Norris B; Vandenberg T; Fisher B
J Clin Oncol; 1996 Oct; 14(10):2709-12. PubMed ID: 8874331
[TBL] [Abstract][Full Text] [Related]
2. Phase 2 trial of mifepristone (RU-486) in advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma.
Ramondetta LM; Johnson AJ; Sun CC; Atkinson N; Smith JA; Jung MS; Broaddus R; Iyer RB; Burke T
Cancer; 2009 May; 115(9):1867-74. PubMed ID: 19241422
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine.HCl and doxorubicin chemotherapy in metastatic breast cancer: A National Cancer Institute of Canada clinical trials group study.
Khoo K; Brandes L; Reyno L; Arnold A; Dent S; Vandenberg T; Lebwohl D; Fisher B; Eisenhauer E
J Clin Oncol; 1999 Nov; 17(11):3431-7. PubMed ID: 10550138
[TBL] [Abstract][Full Text] [Related]
4. Mifepristone as treatment of recurrent progesterone receptor-positive uterine leiomyosarcoma.
Koivisto-Korander R; Leminen A; Heikinheimo O
Obstet Gynecol; 2007 Feb; 109(2 Pt2):512-4. PubMed ID: 17267877
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of mifepristone (RU486) in refractory ovarian cancer.
Rocereto TF; Saul HM; Aikins JA; Paulson J
Gynecol Oncol; 2000 Jun; 77(3):429-32. PubMed ID: 10831354
[TBL] [Abstract][Full Text] [Related]
6. Mifepristone. Auxiliary therapeutic use in cancer and related disorders.
Koide SS
J Reprod Med; 1998 Jul; 43(7):551-60. PubMed ID: 9693404
[TBL] [Abstract][Full Text] [Related]
7. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype.
Rakha EA; El-Sayed ME; Green AR; Paish EC; Powe DG; Gee J; Nicholson RI; Lee AH; Robertson JF; Ellis IO
J Clin Oncol; 2007 Oct; 25(30):4772-8. PubMed ID: 17876012
[TBL] [Abstract][Full Text] [Related]
8. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
Gelmon KA; Tischkowitz M; Mackay H; Swenerton K; Robidoux A; Tonkin K; Hirte H; Huntsman D; Clemons M; Gilks B; Yerushalmi R; Macpherson E; Carmichael J; Oza A
Lancet Oncol; 2011 Sep; 12(9):852-61. PubMed ID: 21862407
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.
Goss PE; Clark RM; Ambus U; Weizel HA; Wadden NA; Crump M; Walde D; Tye LM; De Coster R; Bruynseels J
Clin Cancer Res; 1995 Mar; 1(3):287-94. PubMed ID: 9815984
[TBL] [Abstract][Full Text] [Related]
10. RU486 (mifepristone): mechanisms of action and clinical uses.
Cadepond F; Ulmann A; Baulieu EE
Annu Rev Med; 1997; 48():129-56. PubMed ID: 9046951
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of the progesterone receptor antagonist mifepristone for palliative therapy of patients with a variety of advanced cancer types.
Check JH; Dix E; Cohen R; Check D; Wilson C
Anticancer Res; 2010 Feb; 30(2):623-8. PubMed ID: 20332480
[TBL] [Abstract][Full Text] [Related]
12. Mifepristone: antineoplastic studies.
Sartor O; Figg WD
Clin Obstet Gynecol; 1996 Jun; 39(2):498-505. PubMed ID: 8734014
[TBL] [Abstract][Full Text] [Related]
13. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
Gianni L; Romieu GH; Lichinitser M; Serrano SV; Mansutti M; Pivot X; Mariani P; Andre F; Chan A; Lipatov O; Chan S; Wardley A; Greil R; Moore N; Prot S; Pallaud C; Semiglazov V
J Clin Oncol; 2013 May; 31(14):1719-25. PubMed ID: 23569311
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab retreatment after relapse on adjuvant trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer: final results of the Retreatment after HErceptin Adjuvant trial.
Láng I; Bell R; Feng FY; Lopez RI; Jassem J; Semiglazov V; Al-Sakaff N; Heinzmann D; Chang J
Clin Oncol (R Coll Radiol); 2014 Feb; 26(2):81-9. PubMed ID: 24051172
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. Breast Cancer Site Group.
Pritchard KI; Paterson AH; Fine S; Paul NA; Zee B; Shepherd LE; Abu-Zahra H; Ragaz J; Knowling M; Levine MN; Verma S; Perrault D; Walde PL; Bramwell VH; Poljicak M; Boyd N; Warr D; Norris BD; Bowman D; Armitage GR; Weizel H; Buckman RA
J Clin Oncol; 1997 Jun; 15(6):2302-11. PubMed ID: 9196144
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group.
Trudeau ME; Eisenhauer EA; Higgins BP; Letendre F; Lofters WS; Norris BD; Vandenberg TA; Delorme F; Muldal AM
J Clin Oncol; 1996 Feb; 14(2):422-8. PubMed ID: 8636752
[TBL] [Abstract][Full Text] [Related]
17. Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer.
Robert NJ; Conkling PR; O'Rourke MA; Kuefler PR; McIntyre KJ; Zhan F; Asmar L; Wang Y; Shonukan OO; O'Shaughnessy JA
Breast Cancer Res Treat; 2011 Feb; 126(1):101-8. PubMed ID: 21188632
[TBL] [Abstract][Full Text] [Related]
18. Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone.
Grunberg SM; Weiss MH; Spitz IM; Ahmadi J; Sadun A; Russell CA; Lucci L; Stevenson LL
J Neurosurg; 1991 Jun; 74(6):861-6. PubMed ID: 2033444
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study.
Ravdin PM; Green S; Dorr TM; McGuire WL; Fabian C; Pugh RP; Carter RD; Rivkin SE; Borst JR; Belt RJ
J Clin Oncol; 1992 Aug; 10(8):1284-91. PubMed ID: 1634918
[TBL] [Abstract][Full Text] [Related]
20. Hormonal therapy plus bevacizumab in postmenopausal patients who have hormone receptor-positive metastatic breast cancer: a phase II Trial of the Sarah Cannon Oncology Research Consortium.
Yardley DA; Burris HA; Clark BL; Shipley D; Rubin M; Barton J; Arrowsmith E; Hainsworth JD
Clin Breast Cancer; 2011 Jun; 11(3):146-52. PubMed ID: 21665134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]